<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39312097</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1568-5608</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Inflammopharmacology</Title><ISOAbbreviation>Inflammopharmacology</ISOAbbreviation></Journal><ArticleTitle>The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10787-024-01568-y</ELocationID><Abstract><AbstractText>The relation between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and severity of COVID-19 has been the subject to debate since the outbreak of the pandemic. Despite speculations about the possible harmful or protective effects, the position currently most supported by the scientific community is that there is no association between use of NSAIDs and COVID-19 outcomes. With the aim of contributing to increase the body of evidence on this issue, we conducted a case-control study using real-world data to investigate the association between prior use of NSAIDs, by active ingredient and type (traditional NSAIDs and selective COX-2 inhibitors), and important COVID-19-related outcomes, including susceptibility, PCR + patient progression, and hospitalisation. Our findings suggest that, in general, the use of traditional NSAIDs is not associated with any adverse COVID-19 outcome. However, we observed a possible association between diclofenac and a higher risk of PCR + patient progression. Our results also suggest that selective COX-2 inhibitors might be related with a reduction in the risk of PCR + patient progression. These results suggest that, with the possible exception of diclofenac, the use of NSAIDs should not be advised against for relief of symptoms in patients with COVID-19. In addition, they support the importance of continue to investigate the treatment potential of selective COX-2 inhibitors in the management of COVID-19, something that could have significant implications for the treatment of this disease and other viral infections.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mallah</LastName><ForeName>Narmeen</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3711-3792</Identifier><AffiliationInfo><Affiliation>Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Institute of Health Research of Santiago de Compostela de Compostela, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consortium for Biomedical Research in Epidemiology &amp; Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/ San Francisco s/n, 15782, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visos-Varela</LastName><ForeName>Irene</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-6466-6213</Identifier><AffiliationInfo><Affiliation>Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Institute of Health Research of Santiago de Compostela de Compostela, Santiago de Compostela, Spain. irene.visos.varela@usc.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain. irene.visos.varela@usc.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/ San Francisco s/n, 15782, Santiago de Compostela, Spain. irene.visos.varela@usc.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takkouche</LastName><ForeName>Bahi</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-0739-2241</Identifier><AffiliationInfo><Affiliation>Consortium for Biomedical Research in Epidemiology &amp; Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/ San Francisco s/n, 15782, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Research of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bugarín-González</LastName><ForeName>Rosendo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centro de Salud de Monforte de Lemos, Área Sanitaria de Lugo, A Mariña e Monforte de Lemos, SERGAS, Monforte de Lemos, Lugo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piñeiro-Lamas</LastName><ForeName>María</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3655-100X</Identifier><AffiliationInfo><Affiliation>Consortium for Biomedical Research in Epidemiology &amp; Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herdeiro</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0500-4049</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, iBiMED-Institute of Biomedicine, University of Aveiro, Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zapata-Cachafeiro</LastName><ForeName>Maruxa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0648-7716</Identifier><AffiliationInfo><Affiliation>Consortium for Biomedical Research in Epidemiology &amp; Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/ San Francisco s/n, 15782, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Research of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez-Fernández</LastName><ForeName>Almudena</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3350-1237</Identifier><AffiliationInfo><Affiliation>Consortium for Biomedical Research in Epidemiology &amp; Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/ San Francisco s/n, 15782, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Research of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salgado-Barreira</LastName><ForeName>Angel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4349-4947</Identifier><AffiliationInfo><Affiliation>Consortium for Biomedical Research in Epidemiology &amp; Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/ San Francisco s/n, 15782, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Research of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueiras</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5766-8672</Identifier><AffiliationInfo><Affiliation>Consortium for Biomedical Research in Epidemiology &amp; Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/ San Francisco s/n, 15782, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Research of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVIDrug Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>COV20/00470</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflammopharmacology</MedlineTA><NlmUniqueID>9112626</NlmUniqueID><ISSNLinking>0925-4692</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hospitalisation</Keyword><Keyword MajorTopicYN="N">Non-steroidal anti-inflammatory agents</Keyword><Keyword MajorTopicYN="N">Real world-data</Keyword><Keyword MajorTopicYN="N">Susceptibility</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Carracedo-Martínez</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>García-Álvarez</LastName><ForeName>Rosa M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>González-Barcala</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herdeiro</LastName><ForeName>Teresa M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lema-Oreiro</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pintos-Rodríguez</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piñeiro-Lamas</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portela-Romero</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prieto-Campo</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez-Fernández</LastName><ForeName>Almudena</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saez</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taracido-Trunk</LastName><ForeName>Margarita</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39312097</ArticleId><ArticleId IdType="doi">10.1007/s10787-024-01568-y</ArticleId><ArticleId IdType="pii">10.1007/s10787-024-01568-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baghaki S, Yalcin CE, Baghaki HS et al (2020) COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies. Int J Infect Dis 101:29–32. https://doi.org/10.1016/j.ijid.2020.09.1466</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.1466</ArticleId><ArticleId IdType="pubmed">33007455</ArticleId><ArticleId IdType="pmc">7525269</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown H, Prescott R (2015) Applied mixed models in medicine. Wiley</Citation></Reference><Reference><Citation>Bruce E, Barlow-Pay F, Short R et al (2020) Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19. J Clin Med 9:2586. https://doi.org/10.3390/jcm9082586</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9082586</ArticleId><ArticleId IdType="pubmed">32785086</ArticleId><ArticleId IdType="pmc">7465199</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell HM, Murata AE, Conner TA, Fotieo G (2022a) Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19. PLoS ONE 17:e0267462. https://doi.org/10.1371/journal.pone.0267462</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0267462</ArticleId><ArticleId IdType="pubmed">35511939</ArticleId><ArticleId IdType="pmc">9071138</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JI, Dubois MM, Savage TJ et al (2022b) Comorbidities Associated with Hospitalization and Progression Among Adolescents with Symptomatic Coronavirus Disease 2019. J Pediatr 245:102-110.e2. https://doi.org/10.1016/j.jpeds.2022.02.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2022.02.048</ArticleId><ArticleId IdType="pubmed">35240138</ArticleId><ArticleId IdType="pmc">8883759</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow JH, Khanna AK, Kethireddy S et al (2021) Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients With Coronavirus Disease 2019. Anesth Analg 132:930–941. https://doi.org/10.1213/ANE.0000000000005292</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000005292</ArticleId><ArticleId IdType="pubmed">33093359</ArticleId></ArticleIdList></Reference><Reference><Citation>Consolaro E, Suter F, Rubis N et al (2022) A home-treatment algorithm based on anti-inflammatory drugs to prevent hospitalization of patients with early COVID-19: a matched-cohort study (COVER 2). Front Med 9:785785. https://doi.org/10.3389/fmed.2022.785785</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.785785</ArticleId></ArticleIdList></Reference><Reference><Citation>de Abajo FJ, Rodríguez-Martín S, Lerma V et al (2020) Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. The Lancet 395:1705–1714. https://doi.org/10.1016/S0140-6736(20)31030-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31030-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Díez-Fuertes F, Iglesias-Caballero M, García-Pérez J et al (2021) A founder effect led early SARS-CoV-2 transmission in Spain. J Virol 95:e01583-e1620. https://doi.org/10.1128/JVI.01583-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01583-20</ArticleId><ArticleId IdType="pubmed">33127745</ArticleId><ArticleId IdType="pmc">7925114</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrini P, Schilte MN, Zareie M et al (2009) Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis. Nephrol Dial Transplant 24:3669–3676. https://doi.org/10.1093/ndt/gfp384</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfp384</ArticleId><ArticleId IdType="pubmed">19666665</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Tiseo G, Valoriani B et al (2021) Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. Infect Dis Ther 10:2479–2488. https://doi.org/10.1007/s40121-021-00525-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00525-4</ArticleId><ArticleId IdType="pubmed">34435337</ArticleId><ArticleId IdType="pmc">8386337</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21. https://doi.org/10.1016/S2213-2600(20)30116-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30116-8</ArticleId><ArticleId IdType="pubmed">32171062</ArticleId><ArticleId IdType="pmc">7118626</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton L, Gribben C, Caldwell D et al (2021) Risk of hospital admission with covid-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case–control study. BMJ 374:n2060. https://doi.org/10.1136/bmj.n2060</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2060</ArticleId><ArticleId IdType="pubmed">34470747</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Álvarez RM, Zapata-Cachafeiro M, Visos-Varela I et al (2024) Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient. Inflammopharmacology 32:1805–1815. https://doi.org/10.1007/s10787-024-01475-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-024-01475-2</ArticleId><ArticleId IdType="pubmed">38619761</ArticleId><ArticleId IdType="pmc">11136854</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaznavi H, Mohammadghasemipour Z, Shirvaliloo M et al (2022) Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients. Inflammopharmacology 30:1645–1657. https://doi.org/10.1007/s10787-022-01029-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-01029-4</ArticleId><ArticleId IdType="pubmed">35834150</ArticleId><ArticleId IdType="pmc">9281238</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Hiatt J, Bouhaddou M et al (2020) Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370:eabe9403. https://doi.org/10.1126/science.abe9403</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe9403</ArticleId><ArticleId IdType="pubmed">33060197</ArticleId><ArticleId IdType="pmc">7808408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Gonzalez-Rojas Y, Juarez E et al (2022) Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 327:1236–1246. https://doi.org/10.1001/jama.2022.2832</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.2832</ArticleId><ArticleId IdType="pubmed">35285853</ArticleId><ArticleId IdType="pmc">8922199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W, Chen Y, You K et al (2020) Celebrex adjuvant therapy on coronavirus disease 2019: an experimental study. Front Pharmacol. https://doi.org/10.3389/fphar.2020.561674</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.561674</ArticleId><ArticleId IdType="pubmed">33708125</ArticleId><ArticleId IdType="pmc">7770469</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber CA, Szucs TD, Rapold R, Reich O (2013) Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. BMC Public Health 13:1030. https://doi.org/10.1186/1471-2458-13-1030</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-13-1030</ArticleId><ArticleId IdType="pubmed">24172142</ArticleId><ArticleId IdType="pmc">3840632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong HE, Lee H, Shin HJ et al (2021) Association between nonsteroidal antiinflammatory drug use and adverse clinical outcomes among adults hospitalized with coronavirus 2019 in South Korea: a nationwide study. Clin Infect Dis off Publ Infect Dis Soc Am 73:e4179–e4188. https://doi.org/10.1093/cid/ciaa1056</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow CS, Hasan SS (2021) The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs: a meta-analysis. Inflammopharmacology 29:641–644. https://doi.org/10.1007/s10787-021-00810-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-021-00810-1</ArticleId><ArticleId IdType="pubmed">33881684</ArticleId><ArticleId IdType="pmc">8059110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kun Á, Hubai AG, Král A et al (2023) Do pathogens always evolve to be less virulent? The virulence–transmission trade-off in light of the COVID-19 pandemic. Biol Futura. https://doi.org/10.1007/s42977-023-00159-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42977-023-00159-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Laughey W, Lodhi I, Pennick G et al (2023) Ibuprofen, other NSAIDs and COVID-19: a narrative review. Inflammopharmacology 31:2147–2159. https://doi.org/10.1007/s10787-023-01309-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01309-7</ArticleId><ArticleId IdType="pubmed">37603158</ArticleId><ArticleId IdType="pmc">10518289</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Hilgenfeld R, Whitley R, De Clercq E (2023) Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov 22:449–475. https://doi.org/10.1038/s41573-023-00672-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-023-00672-y</ArticleId><ArticleId IdType="pubmed">37076602</ArticleId><ArticleId IdType="pmc">10113999</ArticleId></ArticleIdList></Reference><Reference><Citation>Micallef J, Soeiro T, Jonville-Béra A-P (2020) Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie 75:355–362. https://doi.org/10.1016/j.therap.2020.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2020.05.003</ArticleId><ArticleId IdType="pubmed">32418728</ArticleId><ArticleId IdType="pmc">7204680</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore N, Bosco-Levy P, Thurin N et al (2021) NSAIDs and COVID-19: a systematic review and meta-analysis. Drug Saf 44:929–938. https://doi.org/10.1007/s40264-021-01089-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-021-01089-5</ArticleId><ArticleId IdType="pubmed">34339037</ArticleId><ArticleId IdType="pmc">8327046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Tan WYT, Chan Y et al (2020) Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. Clin Transl Immunol 9:e1159. https://doi.org/10.1002/cti2.1159</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1159</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico N, Cortinovis M, Suter F, Remuzzi G (2023) Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. Lancet Infect Dis 23:e22–e33. https://doi.org/10.1016/S1473-3099(22)00433-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00433-9</ArticleId><ArticleId IdType="pubmed">36030796</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Smith CJ, Roffe C et al (2021) Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case–control study. J Neurol Neurosurg Psychiatry 92:242–248. https://doi.org/10.1136/jnnp-2020-324927</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-324927</ArticleId><ArticleId IdType="pubmed">33154179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro J, Bates D (2000) Mixed-effects models in S and S-PLUS. Springer Science &amp; Business Media, Berlin</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4419-0318-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose S, van der Laan MJ (2009) Why match? Investigating matched case-control study designs with causal effect estimation. Int J Biostat. https://doi.org/10.2202/1557-4679.1127</Citation><ArticleIdList><ArticleId IdType="doi">10.2202/1557-4679.1127</ArticleId><ArticleId IdType="pubmed">20231866</ArticleId><ArticleId IdType="pmc">2827892</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ, Greenland S, Lash TL (2008) Case–control studies. In: Melnick EL, Everitt BS (eds) Encyclopedia of quantitative risk analysis and assessment. Wiley, Hoboken</Citation></Reference><Reference><Citation>Spila Alegiani S, Crisafulli S, Giorgi Rossi P et al (2021) Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatol Oxf Engl 60:SI5–SI36. https://doi.org/10.1093/rheumatology/keab348</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab348</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup WW (2012) Generalized linear mixed models: modern concepts, methods and applications. CRC Press</Citation></Reference><Reference><Citation>Théophile H, Laporte J-R, Moore N et al (2011) The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf 34:861–868. https://doi.org/10.2165/11592140-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11592140-000000000-00000</ArticleId><ArticleId IdType="pubmed">21879780</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H-C, Lin C-C, Hsiao L-D, Yang C-M (2019) Lysophosphatidylcholine-induced mitochondrial fission contributes to collagen production in human cardiac fibroblasts[S]. J Lipid Res 60:1573–1589. https://doi.org/10.1194/jlr.RA119000141</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.RA119000141</ArticleId><ArticleId IdType="pubmed">31363041</ArticleId><ArticleId IdType="pmc">6718437</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaja R, Chan JSK, Ferreira P et al (2021) The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections. Br J Clin Pharmacol 87:776–784. https://doi.org/10.1111/bcp.14514</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14514</ArticleId><ArticleId IdType="pubmed">32805057</ArticleId></ArticleIdList></Reference><Reference><Citation>Visos-Varela I, Zapata-Cachafeiro M, Piñeiro-Lamas M et al (2023a) Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: a population-based study. Eur Neuropsychopharmacol 71:96–108. https://doi.org/10.1016/j.euroneuro.2023.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2023.03.011</ArticleId><ArticleId IdType="pubmed">37094487</ArticleId><ArticleId IdType="pmc">10070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Visos-Varela I, Zapata-Cachafeiro M, Pintos-Rodríguez S et al (2023b) Outpatient atorvastatin use and severe COVID-19 outcomes: A population-based study. J Med Virol 95:e28971. https://doi.org/10.1002/jmv.28971</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28971</ArticleId><ArticleId IdType="pubmed">37486310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousefifard M, Zali A, Zarghi A et al (2020) Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence. Int J Clin Pract 74:e13557. https://doi.org/10.1111/ijcp.13557</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13557</ArticleId><ArticleId IdType="pubmed">32460369</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Huang S, Huang S et al (2022) Prevalence of NSAID use among people with COVID-19 and the association with COVID-19-related outcomes: Systematic review and meta-analysis. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.15512.10.1111/bcp.15512</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15512.10.1111/bcp.15512</ArticleId><ArticleId IdType="pubmed">36440759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Zhao S, Gan L et al (2022) Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: a systematic review and meta-analysis. EClinicalMedicine 46:101373. https://doi.org/10.1016/j.eclinm.2022.101373</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101373</ArticleId><ArticleId IdType="pubmed">35434582</ArticleId><ArticleId IdType="pmc">8989274</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>